Explore the words cloud of the HEAL-BY-MIRNA project. It provides you a very rough idea of what is the project "HEAL-BY-MIRNA" about.
The following table provides information about the project.
CENTRO NACIONAL DE INVESTIGACIONESCARDIOVASCULARES CARLOS III (F.S.P.)
|Coordinator Country||Spain [ES]|
|Total cost||149˙750 €|
|EC max contribution||149˙750 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2016-05-01 to 2017-10-31|
Take a look of project's partnership.
|1||CENTRO NACIONAL DE INVESTIGACIONESCARDIOVASCULARES CARLOS III (F.S.P.)||ES (MADRID)||coordinator||149˙750.00|
Mature B cell neoplasias include most of Non-Hodgkin Lymphomas (NHL), such as Diffuse Large B Cell Lymphomas and Burkitt Lymphoma and also B cell Chronic Lymphocytic Leukemia. It is estimated that about 60000-80000 new cases of mature B cell neoplasias are diagnosed every year in Europe. About 60% of NHL present with aggressive forms, and need immediate therapeutic action. The most common choice of treatment for mature B cell neoplasia is chemotherapy, and particularly the multidrug R-CHOP, but a fraction of the cancers either are refractory to these therapeutic interventions or relapse after treatment. Indeed, NHL is the cause of close to 26,000 deaths per year in Europe. Therefore, alternative therapeutic targets are imperative to replace or complement the current approaches. microRNAs (miRNAs) have arisen as extremely promising therapeutic tools in a number of diseases, including cancer. We have identified a miRNA specific of mature B cells whose expression is lost in mature B cell neoplasias. We found that re-introducing this miRNA in lymphoma cells in animal xenograft models leads to a dramatic block of tumor growth and extends mouse survival. Our studies show that this miRNA is therapeutically efficient not only in the form of lentiviral vectors but also as a synthetic miRNA mimic. Likewise, both intratumoral and systemic, intravenous delivery of miRNA mimic have yielded positive regression results. In addition, established lymphoma cell lines as well as primary mature B cell lymphomas have proved sensitive to miRNA treatment. Therefore, we propose to take to proof of concept the idea that miRNA replacement is an efficient therapeutic strategy for the treatment of mature B cell lymphomas. With this HEAL-BY-MIRNA proposal we aim at moving forward this idea to a stage where it can be exploited to have social impact and to become a marketable product.
|year||authors and title||journal||last update|
Nahikari BartolomÃ©-Izquierdo, Virginia G. de YÃ©benes, Angel F. Ãlvarez-Prado, Sonia M. Mur, Juan A. Lopez del Olmo, Sergio Roa, Jesus Vazquez and Almudena R. Ramiro
miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma
published pages: 2408-2419, ISSN: 0006-4971, DOI:
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEAL-BY-MIRNA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "HEAL-BY-MIRNA" are provided by the European Opendata Portal: CORDIS opendata.